<DOC>
	<DOCNO>NCT01622348</DOCNO>
	<brief_summary>The purpose study evaluate different dose level IMO-3100 compare placebo administer 4 week patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Trial IMO-3100 Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>To evaluate safety , tolerability treatment effect different dose level IMO-3100 compare placebo administer 4 week patient moderate severe plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Is age 18 70 year , inclusive ; Completes inform consent procedure ( see Section 15.3 ) , include sign date informed consent form ; Has moderate severe plaque psoriasis meeting criterion specify ; Female subject must negative pregnancy test screen Day 1 prior start treatment ; Female subject childbearing potential ( see Section 8.4.1 ) male subject partner childbearing potential must agree use effective birth control ( contraception ; see Section 8.4.1 ) Screening treatment period four ( 4 ) week last injection study drug . Has know hypersensitivity oligodeoxynucleotide ; Is nurse ; Has body weight &lt; 50 kg ; Has BMI &gt; 34.9 kg/m2 ; Regularly consume &gt; 3 drink alcoholic beverage ( beer , wine , distilled spirit ) per day ; Has positive test antibody human immunodeficiency virus ( HIV1 2 ) hepatitis C virus ; Has positive test hepatitis B surface antigen ( HBsAg ) ; Has screen safety laboratory test meet one follow criterion : hemoglobin &lt; 10.5 g/dL white blood cell count &lt; 4,000 cells/mm3 absolute neutrophil count ( ANC ) &lt; 1500/mm3 platelet count &lt; 100,000/mm3 alanine transaminase ( ALT ; SGPT ) &gt; 1.5x ULN aspartate transaminase ( AST ; SGOT ) &gt; 1.5x ULN serum total bilirubin &gt; 1.4x ULN serum creatinine &gt; 1.3x ULN ; Has history allogeneic organ transplant ( include bone marrow stem cell ) ; Has , within past 10 year , evidence require treatment cancer ( except treat basal squamous cell carcinoma skin cure cervical carcinomainsitu ) ; Has within past three month expect study period follow treatment : surgery require general anesthesia hematopoietic stimulating agent ( e.g. , erythropoietin , GCSF , GMCSF ) another investigational drug ; Has significant medical disease ( chronic active within past 6 month ) , include , limited : cardiac disease ( e.g. , unstable angina , myocardial infarction , congestive heart failure , ventricular arrhythmia ) ; uncontrolled seizure disorder ; liver disease ; chronic infection ( e.g. , tuberculosis ) ; uncontrolled diabetes ; Has condition would , opinion Investigator , potentially compromise safety compliance patient may preclude patient 's successful completion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
</DOC>